Article Text
Abstract
The US Food and Drug Administration (FDA) issues warning letters to all research stakeholders if unacceptable deficiencies are found during site visits. Warning letters issued by the FDA between January 2011 and December 2012 to clinical investigators and institutional review boards (IRBs) were reviewed for various violation themes and compared to similar studies in the past. Warning letters issued to sponsors between January 2005 and December 2012 were analysed for the first time for a specific set of violations using descriptive statistics. Failure to protect subject safety and to report adverse events to IRBs was found to be significant compared to prior studies for clinical investigators, while failure to follow standard operating procedures and maintain documentation was noted as significant in warning letters to IRBs. Failure to maintain minutes of meeting and to follow written procedures for continuing review were new substantial violations in warning letters issued to IRBs. Forty-six warning letters were issued to sponsors, the most common violations being failure to follow a monitoring schedule (58.69%), failure to obtain investigator agreement (34.78%), failure to secure investigators’ compliance (30.43%), and failure to maintain data records and ship documents to investigators (30.43%). Appropriate methods for handling clinical trial procedural violations should be developed and implemented worldwide.
- Clinical Trials
- Ethics Committees/Consultation
- Legal Aspects
- Research Ethics
- Informed Consent
Statistics from Altmetric.com
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Read the full text or download the PDF:
Other content recommended for you
- Failure to adhere to study plans is the most common research error among US investigators
- Understanding FDA Regulatory Requirements for Investigational New Drug Applications for Sponsor - Investigators
- Understanding Food and Drug Administration Regulatory Requirements for an Investigational Device Exemption for Sponsor - Investigators
- Streamlining the Clinical Research Enterprise
- Investigational New Drug applications: a 1 - year pilot study on rates and reasons for clinical hold
- Recommendations From the Investigational New Drug / Investigational Device Exemption Task Force of the Clinical and Translational Science Award Consortium
- Clinical Research From Proposal to Implementation
- NANOSCIENCE AND NANOTECHNOLOGY IN BIOLOGY AND MEDICINE (R01): PA-11-148
- A qualitative study of institutional review board members ’ experience reviewing research proposals using emergency exception from informed consent
- Study protocol of RESCUE - ALS: A Phase 2, randomised, double - blind, placebo - controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM - Au8 as a mechanism to slow disease progression